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Effect of intraperitoneat neostigmine on peritoneal transport charac-
teristics in CAPD. Lymphatics have been suggested to play a major role
in the absorption of dialysate, which consequently affects the adequacy
of peritoneal dialysis. Neostigmine has been found to decrease lym-
phatic absorption in rats, presumably by causing constriction of the
lymphatic stomata. We investigated the effect of neostigmine on seven
continuous ambulatory peritoneal dialysis (CAPD) patients in a pro-
spective study. We performed modified peritoneal equilibration tests
both with and without intraperitoneal neostigmine in a random order.
Radiolabeled albumin (0.8 mg) was added to 2 liters of dialysate 2.0
mg neostigmine. We evaluated ultrafiltration and creatinine, phosphate,
and urea clearances. The dialysate bag and the peritoneum were
scanned at the initiation and conclusion of the four-hour dwell period.
We found no change in ultrafiltration, residual volumes, creatinine,
phosphate and urea clearances, or albumin recovered. Of the seven
patients exposed to neostigmine, four had diarrhea, abdominal cramps,
nausea, and vomiting. In conclusion, we found that 2 mg i.p. neostig-
mine did cause significant side-effects and did not alter transport
characteristics in CAPD patients.
Lymphatic absorption in peritoneal dialysis has been said to
play a significant role in decreasing net ultrafiltration [1].
Decreasing the magnitude of lymphatic reabsorption would
enhance net ultrafiltration and improve clearances, which has
obvious practical importance in improving the adequacy of
dialysis. Additionally, altering lymphatic reabsorption may
alleviate the loss of ultrafiltration seen in some patients [2, 3].
Neostigmine and phosphatidyicholine may decrease lymphatic
absorption by causing constriction of the lymphatic stomata [4,
5]. Clinical trials utilizing phosphatidyicholine have been con-
flicting. Several authors found ultrafiltration improved in those
with low ultrafiltration [3, 6] while others found that phosphati-
dyicholine did not alter ultrafiltration characteristics [7—9].
Mactier et al [4] demonstrated that neostigmine reduced lym-
phatic absorption in rats, and hence increased net ultrafiltration
and solute clearances. Because similar data for humans are
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unavailable, we embarked upon a prospective, randomized trial
in CAPD patients in an effort to improve the efficiency of
peritoneal dialysis.
Methods
Patients stable on CAPD for greater than three months,
without peritonitis during the last three months, and without
ultrafiltration problems gave written informed consent and were
enrolled in the prospective study. Seven of 18 patients at our
center who met the criteria agreed to participate. The study was
approved by our Institutional Review Committee. One patient
completed only the neostigmine peritoneal equilibration tests
(PET) secondary to a cerebrovascular accident, unrelated to the
study; hence, this patient is included only in side-effect and
epidemiologic data.
We performed modified PET [10] with and without neostig-
mine (2.0 mg i.p.) in a random order. The modifications made to
the PET included: the addition of albumin and neostigmine to
the dialysate; measuring phosphate; and only sampling at 0,
120, and 240 minutes. The studies were performed one to six
weeks apart at 8:00 a.m. A PET done within six months of the
study was also reviewed.
One mCi of Tc labeled human serum albumin (0.8 mg) was
added to the 2 liters of 2.5% dextrose dialysate (Abbott, Abbott
Park, Illinois; or Baxter, Deerfield, Illinois, USA). A large field
of view scintillation camera with an all purpose collimator
obtained two minute counts over the full dialysate bag. All
subsequent counts were obtained at a constant distance. The
intraperitoneally-instilled radioactive dialysate was then al-
lowed to equilibrate. Images were obtained over the peritoneum
as well as heart, lung, and thighs. The latter areas were used to
demonstrate the absence of significant systemic or lymphatic
activity. Following a four-hour dwell time, the dialysate was
drained from the peritoneum and the patient was again imaged
as described above as well as the bag of drained fluid. Regions
of interest were drawn around the peritoneum, lungs, heart,
thigh, and bag on each imaging occasion and two minute counts
recorded. All counts were decay corrected.
Ratios were calculated in the following manner. The dialysate
bag was counted before instillation and again following drainage
from the peritoneum at four hours. After decay correction, the
ratio of counts in the bag after draining the peritoneum versus
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Table 1. Residual and total volumes in control and neostigmine
exchange
Patient UP control
UF
neostigmine
Residual
volume
control
Residual
volume
neostigmine
1 2575 2550 279 263
2 3425 2825 301 202
3 2075 2450 369 479
4 2550 2750 352 369
5 2300 2000 569 513
6 2425 2500 351 487
Mean 2558 462.5a 2512 290.5a 407b 399b
Values are expressed standard deviation.
a 0.76 comparing UP volumes in each patient during control versus
neostigmine PETb 0.84 comparing residual volumes during control and neostigmine
PET
counts in the bag prior to instillation was calculated as "recov-
erable counts." The amount of radiolabeled albumin recovered
should increase as the magnitude of lymphatic absorption
decreases.
Blood and dialysate samples were analyzed (Ektachem,
Kodak, Rochester, New York, USA) for urea using a urease
method, creatinine using an enzymatic peroxidase method, and
phosphorus using an ammonium molybdate method. Clear-
ances of creatinine, urea, and phosphorus were calculated as C
= (DIP) x (Vtr), where D = dialysate concentration (mgldl), P
= serum concentration (mg/dl), V = dialysate drain volume
(ml), T = time (240 mm). Residual volume (R), that volume of
dialysate remaining in the peritoneal cavity after drainage, was
calculated using the formula [10]: R = V.(S3 — S2)I(S1 — S3),
where Vm instillation volume, S1 = solute concentration in
dialysate drained prior to PET initiation, S2 solute concen-
tration in dialysate instilled, and S3 = solute concentration
immediately post-instillation at zero dwell time. Side-effects
were noted by a dialysis technician. Holter monitor studies
were done both during the control and the neostigmine PETs.
Statistical analysis was by the Student's paired t-test for
paired data. The Tukey-Kramer Multiple Comparison Test was
used for the analysis of change with time. Values are expressed
in mean standard deviation.
Results
Our patients ranged in age from 21 to 59 with a mean of 47
years. There were five males and two females. The etiology of
renal failure was diabetes mellitus in two, hypertension in two,
autosomal dominant polycystic kidney disease in two, and one
with sarcoidosis. The patients' medications remained constant
throughout the study; all were on a vitamin, iron preparation,
phosphate binders, and stool softeners. One patient was taking
a beta blocker; one, an alpha adrenergic agent; one, a nonste-
roidal anti-inflammatory drug; and one, a cholesterol lowering
agent. None was taking lecithin, calcium channel blockers or
chlorpromazine. Four patients received neostigmine first; two
patients received the control exchange first.
Residual volumes ranged from 202 to 569 ml (Table 1), the
mean difference was 8 ml, mean residual volumes in control and
neostigmine exchange were 407 115 ml and 399 96 ml,
respectively (P 0.84). Total dialysate volume was 2,512 291
ml with neostigmine and 2,558 463 ml without neostigmine (P
Table 2. Clearance data
With
neostigmine(N=6)
Without
neostigmine(N=6) P
Creatinine clearance 6.2 1.17 6.1 1.12 0.87
cc/mm
Urea clearance cc/mm 9.0 1.21 8.9 1.90 0.85
P04 clearance cc/mm
Recovered albumin %
6.7 2.59
70.8 14.15
5.7 1.14
74.3 11.81
0.29
0.77
Values expressed as mean standard deviation.
= 0.76) (Table 1). Comparing ultrafiltration values in the control
PET (2558 462 ml) to PETs (2508 368 ml) done a mean of
6.8 months previously, demonstrated minimal variability (P
0.65). The difference in clearances of creatinine, urea, and
phosphate in patients with and without neostigmine did not
reach statistical significance (Table 2). Our ultrafiltration and
clearance data in patients without neostigmine are similar to
previously reported values [10]. The creatinine and urea D/P
ratios increased at a more rapid rate in the neostigmine treated
exchanges versus the control exchanges, with a significant
difference between neostigmine and control at two hours but
not at four hours. There was no difference in DIP ratio phos-
phate between the two exchanges (Table 3). Recovered albumin
was 70.6% with neostigmine and 74.3% without neostigmine (P
0.77). The heart/lung field of view demonstrated no signifi-
cant activity with nuclear scanning over background and scatter
artifact confirming lack of lymphatic uptake. Four of the seven
patients when exposed to neostigmine experienced nausea,
vomiting, abdominal cramps, and diarrhea. Mean heart rate for
the four hour period or hourly intervals was unchanged; there
were no significant arrhythmias.
Discussion
Our results contradict what has been reported for rats. There
are several potential explanations for the discrepancy between
the rat study and our human study. Firstly, the doses of
neostigmine in the human did not approach those of the rats.
Mactier et a! [4] used a total of 0.126 mgI2O cc dialysate volume
of neostigmine. A similar dose based on 2000 cc dialysate
volume would have been 12.6 mg. We chose a dosage of 2.0 mg
of neostigmine because it is a frequently used clinical dosage.
Despite this dose, patients still had side-effects in the majority
of cases. One patient without symptoms received a repeat study
containing a 5.0 mg dose of neostigmine and did not have
differences in clearances or ultrafiltration as compared with the
initial 2.0 mg dose. Consequently, we do not feel that the dose
was an inadequate dosage or that higher doses would have
provided any additional clinical utility, given the side-effect
profile. Secondly, the lymphatics in humans may be less impor-
tant than lymphatics in rats. Our results demonstrating negligi-
ble amounts albumin tracer in the blood pool would support the
contention of a less important role for the lymphatics in
humans, which concurs with the observation of Rippe, Stelin
and Ahlmdn [11] demonstrating lymph flow of 11 mllhr. How-
ever, Mactier et a! [121 noted the importance of lymphatics in a
patient with ultrafiltration failure, and this was also demon-
strated by Heimburger et al [2]. Olin and Saldeen [13] demon-
strated similar lymphatic pathways in rats and humans. Thirdly,
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Table 3. Dialysate and serum concentrations
Time hours
Control PET Neostigmine PET
0 2 4 0 2 4
DIP creatinine 0.13 0.04 0.38 O.15 0.57 0.14 0.24 0.25 0.56 0.25a 0.59 0.13
DIP urea 0.12 0.05 0.47 0.27a 0.83 0.30 0.19 0.15 0.75 O.17 0.85 0,06
DIP P04 0.05 0.05 0.36 0.16 0.53 0.14 0.02 0.04 0.47 0.13 0.64 0.25
Values are expressed as mean standard deviation.
a P < 0.5 comparing control versus neostigmine values
lymphatics may have increased significance in only those
patients with ultrafiltration failure. This, in part, may explain
the discrepant phosphatidylcholine data between Chan, Abra-
ham and Oreopoulos [6], Di Paolo et al [3], Chan et al [7], and
Dc Vecchi et al [9]. Lymphatics were demonstrated to be of
importance in normal rats by Mactier et al [1] and in humans by
Rippe, Stelin and Ahlmén [14]. Fourthly, the effect of neostig-
mine on the gastrointestinal tract may have adversely affected
ultrafiltration related to volume depletion of the patients sec-
ondary to the nausea, vomiting, and diarrhea. The total period
of time was relatively short, which did not allow a suitable
length of time to become volume depleted and hence did not
affect ultrafiltration volumes. Additionally, the patients with
symptoms did not differ from those without gastrointestinal
symptoms in relation to ultrafiltration and clearances. Time is
another factor that may be critical in explaining discrepant
results of the two studies. The duration of the PET may have
been too prolonged a period, since in Mactier's study of rats the
interval was two hours. The rate of change of the DIP ratio for
creatinine in our study also lends support to this contention. We
picked the four hour period to be able to use a standardized test,
the PET. CAPD patients in general will have dialysate dwelling
for a minimum of four hours and for as long as eight to 12 hours.
While D/P creatinine and urea for the neostigmine exchange
was significantly increased at two hours, the D/P ratio for
phosphate was not. Consequently, we felt the time interval
chosen was reasonable from a clinical perspective. The interval
between studies eliminated the possibility of crossover effect
secondary to neostigmine. Lastly, the number of patients was
admittedly small; however, we are 95%certain that the UF did
not change by 20% or more using a power analysis. In Mactier's
study the ultrafiltration volume increased by 147%. Therefore,
despite the small number of patients, we are certain that
neostigmine in our study did not result in changes of the
magnitude reported in Mactier's study.
Based upon our results, we cannot advocate the use of
neostigmine to alter ultrafiltration volumes or improve clear-
ances. The D/P creatinine and urea data at two hours may
suggest that neostigmine has some utility with shorter dwell
times, that is, in patients on continuous cycling peritoneal
dialysis. This merits further study. In conclusion, our study did
not demonstrate an alteration of ultrafiltration, clearance of
small molecules, or absorption of large molecules that would
only be absorbed by the lymphatics, with the presence of 2.0 mg
of neostigmine intraperitoneally over a four hour period.
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